Emily Esquea, PhD on LinkedIn: #brainmetastasis #cancertherapy (2024)

“By changing the architecture of the ECM to allow for better drug penetration, the LOX inhibitor enables the chemotherapy to stress the tumor into producing more reactive oxygen species (ROS) more effectively. At high enough levels, ROS creates DNA damage that can lead to cell death. Importantly, inhibiting LOX also blocks focal adhesion kinase (FAK) signaling, which would otherwise promote DNA repair. Taken together, these effects can overcome chemotherapy resistance. Further, these effects were found in different types of models, including triple-negative breast cancer cell lines, in vivo models and organoid models created from patient-derived xenografts.”#cancer #breastcancer #cancerresearch #triplenegativebreastcancer #DNArepair #protemics #DNArepair #tumor

1 Comment

🍂 Our September issue is out 🍂Cover: Collective migration shapes heteroclonal cancer cell clusters (Palmiero, M. et al., 2023, doi:10.1002/1878-0261.13369) 👉 Check out the issue at: https://lnkd.in/gHZ9uBVc#cancercellclusters #tumormicroenvironment #glioblastoma #ctDNA #cfDNA #liquidbiopsy

3

New #JITC article: Tumor cell-released autophagosomes (TRAPs) induce PD-L1-decorated NETs that suppress T-cell function to promote breast cancer pulmonary metastasis https://bit.ly/3VKrU56

15

1 Comment

Engineering M13 Bacteriophage for Targeted Photodynamic Cancer TherapyAt Targeting Phage Therapy 2024, Alena Kaltenbrunner from the University of Bologna (Alma Mater Studiorum – Università di Bologna), Italy, presented an insightful oral presentation on this topic. She discussed the innovative use of the M13 bacteriophage in targeted photodynamic cancer therapy, highlighting the latest advancements in nanobiotechnology.#PhageTherapy #Nanobiotechnology #CancerTherapy #PhotodynamicTherapy #UniversityofBologna

9

📄 I am thrilled to share our new publication entitled "Gelatin nanoparticles loaded with 3-alkylpyridinium salt APS7, an analog of marine toxin, are a promising support in human lung cancer therapy."You can read the full article here: https://lnkd.in/dGqcinCt.

12

Cancer Early Diagnosis#ISET detects circulating #tumour cells (CTCs). CTCs are isolated by mechanical filtration. Using cytology, it is possible to identify which organ they come from. This detection happens even if the imaging detects nothing. ISET allows the detection of tumours at very early stages. CTCs are the tumor cells, that circulate in the blood, that are responsible for future metastases.Unlike other methods, ISET does not produce false negatives or false positives.https://lnkd.in/de3P4-Bn.Book - Patrizia Paterlini Bréchot - Matar o CancroFounder and President at Rarecells, Professor at Université de Parishttps://lnkd.in/dkmNnTTi#cancer #ctc #ccc #cancerdetection #cancerdiagnosis

1 Comment

A first patient has been dosed in a Phase I study of Telix’s investigational therapy in patients with newly diagnosed glioblastoma, the most common and aggressive form of brain cancer.TLX101 (131I-IPA) is a novel approach that is readily able to pass through the blood-brain barrier - the normal protective barrier that prevents many potential drug candidates entering the brain.Building on data generated in the IPAX-1 study, IPAX-2 will evaluate whether the observed safety and drug interaction profile remains suitable in a front-line setting before progressing to a label-indicating Phase II study.Read more here: https://lnkd.in/gzxncb74

472

4 Comments

Exciting progress in cancer treatment! This new cellular immunotherapy approach from the NCI Center for Cancer Research shows promising early results in reducing tumor size and preventing regrowth in metastatic solid tumors. Looking forward to seeing how this develops further. #CancerResearch #Immunotherapy #MedicalBreakthroughs

3

In this edition, we are sharing an update on the:💡 Selective RET Inhibitor SelpercatinibDemonstrated Favorable Clinical Outcome over Cabozantinib or Vandetanib inRET-mutant Medullary Thyroid Cancer.💡 DESTINY-PanTumor02: The ADCtrastuzumab deruxtecan (T-DXd) showedactivity in HER2-expressing solid tumors.💡 Detection Discrepancies in HER2 Amplification:Implications for Therapeutic Strategies - Insights from the MOUNTAINEER StudyPresented at the 2023 #ASCOand #ESMO Annual Meetings.Find out more on our #ACTGenomics Blog:https://lnkd.in/g-WU-Upi

8

Good description for clinical trials in oncologic patients concerning quality of life European Neuroendocrine Tumor Society e.V. (ENETS) Neuroendocrine Cancer UK Neuroendocrine Tumor Research Foundation Roche Novartis and showing how multifaceted, risky and difficult a good NET treatment is!

2